Amphastar Pharmaceuticals, Inc (AMPH) Stock Analysis
Verdict: WATCH (do not buy)
Collapsing earnings quality and consecutive guidance misses have neutralized Amphastar's valuation appeal, turning it into a falling knife.
Investment score: 42/100
Analysis as of
Is Amphastar Pharmaceuticals, Inc stock worth reviewing? The TradeMates thesis
Amphastar is currently a value trap characterized by negative growth and collapsing analyst confidence despite strong cash flows.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 25/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Amphastar Pharmaceuticals, Inc opportunities and risks
What speaks for AMPH
- High Free Cash Flow Yield
What speaks against AMPH
- Earnings Quality Erosion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AMPH | 10.9x | 1.1x | 7.0x | 47.3% | 11.0% | 16.4% |
| LXRX | n/a | 14.6x | n/a | 99.1% | -37.5% | -3.8% |
| LBRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.0% |
| BIOA | n/a | 79.5x | n/a | 99.4% | -871.8% | -10.8% |
| PHAT | n/a | 4.5x | n/a | 84.9% | -76.8% | -10.7% |
| NIKA | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
| Peer median | n/a | 4.5x | n/a | 84.9% | -37.5% | -5.0% |
Frequently asked questions about Amphastar Pharmaceuticals, Inc (AMPH)
Is AMPH stock a good investment?
The TradeMates model rates Amphastar Pharmaceuticals, Inc as WATCH (do not buy) with an investment score of 42/100. Amphastar is currently a value trap characterized by negative growth and collapsing analyst confidence despite strong cash flows. This is algorithmic model output, not personal investment advice.
Is AMPH stock a buy?
The TradeMates model verdict for AMPH is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.